TB-500 (Thymosin Beta-4) | Research-Grade Peptide

AUD $225

For laboratory research use only. Not for human use.

Research-grade TB-500 — the synthetic form of Thymosin Beta-4 (Tβ4). Studied in preclinical models for actin regulation, tissue repair, angiogenesis, and inflammation modulation. Third-party HPLC tested to ≥98% purity. For laboratory research use only.

Supply Specifications

PeptideTB-500 (Ac-LKKTETQ) — Thymosin Beta-4 fragment
Molecular weight831.0 Da
FormatLyophilised powder
Purity≥98% by HPLC
TestingThird-party HPLC + Mass Spec
Storage-20°C lyophilised; 2–8°C reconstituted
UseLaboratory research use only
PriceAUD $225

Research Summary

TB-500 is a synthetic peptide corresponding to the active region (amino acids 17-23) of Thymosin Beta-4. Its primary mechanism involves binding to G-actin and preventing polymerisation into F-actin, facilitating cell migration — a critical process in tissue repair.

Preclinical studies in rodent models have observed apparent acceleration of wound closure, tendon repair, and muscle regeneration. TB-500 is frequently studied in combination with BPC-157, as the two peptides are thought to act through complementary mechanisms.

TB-500 is not TGA-approved for human use in Australia. Available for laboratory research use only.

Related Research

  • TB-500 Australia: Complete Research Guide
  • BPC-157 and TB-500 Research Stack Overview
  • BPC-157 Research Peptide

Disclaimer: All products supplied by PeptideIQ are for laboratory research use only. They are not approved for human use, consumption, or therapeutic application. PeptideIQ complies with all applicable Australian regulations including the Therapeutic Goods Act 1989.